Inflammation and ischaemic stroke: Current status and future perspectives;Inflammation et accident ischémique cérébral aigu. Données actuelles et perspectives

Revue Neurologique

Volumn 161, Issue 12, 2005, Pages 1177-1182

  Samson, Y ^a   Lapergue, B ^a   Hosseini, H ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Adhesion molecules; Inflammation; Ischemia; Neuroprotection; Stroke

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INSULIN; INTEGRIN; SELECTIN;

BLOOD BRAIN BARRIER; BODY TEMPERATURE; CEREBROVASCULAR ACCIDENT; CORRELATION ANALYSIS; DATA ANALYSIS; HUMAN; HYPOTHERMIA; INFLAMMATION; LEUKOCYTE; MICROGLIA; REVIEW;

EID: 30944436675     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(05)85190-2     Document Type: Article

References (29)

1. BECKER KJ. (1998). Inflammation and acute stroke. Curr Opin Neurol, 11: 45-49.
2. BOYSEN G, CHRISTENSEN H. (2001). Stroke severity determines body temperature in acute stroke. Stroke, 32: 413-417.
3. DANTON GH, DIETRICH WD. (2003). Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol, 62: 127-136.
4. DAS UN, UNDURTI N. (2001). Das, Is Insulin an Antiinflammatory Molecule? Nutrition, 17: 409-413.
5. DI NAPOLI M, PAPA F, BOCOLA V. (2001). Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke, 32: 133-138.
6. DI NAPOLI M, PAPA F. (2003). Association Between Blood Pressure and C-Reactive Protein Levels in Acute Ischemic Stroke. Hypertension, 42: 1117-1123.
7. DI NAPOLI M, PAPA F. (2003). Angiotensin-Converting Enzyme Inhibitor Use Is Associated With Reduced Plasma Concentration of C-Reactive Protein in Patients With First-Ever Ischemic Stroke. Stroke, 34: 2922-2929.
8. ENLIMOMAB ACUTE STROKE TRIAL INVESTIGATORS. (2001). Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology, 57: 1428-1434.
9. FRENETTE PS. (2001). Locking a leucocyte integrin with statins. N Engl J Med, 135: 1419-1421.
10. FRIJNS CJ, KAPPELLE LJ. (2002). Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke, 33: 2115-2122.
11. FURUYA K, TAKEDA H, AZHAR S, MCCARRON R.M, CHEN Y et al. (2001). Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody. Stroke, 32: 2665-2674.
12. HAJAT C, HAJAT S, SHARMA P. (2000). Effects of poststroke pyrexia on stroke outcome: a meta-analysis of studies in patients. Stroke, 31: 410-414.
13. IADECOLA C, ALEXANDER M. (2001). Cerebral ischemia and inflammation. Curr Opin Neurol, 14: 89-94.
14. KRAMS M, LEES KR, HACKE W, GRIEVE AP, ORGOGOZO JM, FORD GA. (2003). Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279, 276 in acute ischemic stroke. Stroke, 34: 2543-2548.
15. LO EH, DALKARA T, MOSKOWITZ MA. (2003). Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci, 4: 399-415.
16. MOCCO J, CHOUDHRI T, HUANG J, HARFELDT E, EFROS L, KLINGBEIL C et al. (2002). HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ Res, 91: 907-914.
17. MONTANER J, CHACON P, KRUPINSKI J, MILLAN M et al. (2004). Safety and Efficacy of Statins in the acute phase of ischemic stroke: the MISTICS Trial. Poster Presentations (P209). 29th International Stroke Conference, San Diego. Stroke, 35: 293.
18. MONTANER J, MOLINA CA, MONASTERIO J et al. (2003). Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation, 107: 598-603.
19. OLSEN TS, WEBER UJ, KAMMERSGAARD LP. (2003). Therapeutic hypothermia for acute stroke. Lancet Neurol, 2: 410-416.
20. PAPPATA S, LEVASSEUR M, GUNN RN et al. (2000). Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195. Neurology, 55: 1052-1054.
21. PFEFFERKORN T, ROSENBERG GA. (2003). Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke, 34: 2025-2030.
22. REITH J, JORGENSEN HS, PEDERSEN PM et al. (1996). Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet, 347: 422-425.
23. ROSENBERG GA. (1998). Matrix metalloproteinase and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke, 29: 2189-2195.
24. ROST NS, WOLF PA, KASE CS et al. (2001). Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke, 32: 2575-2579.
25. SAMSON Y, DELTOUR S, CROZIER S, OBADIA M, BRUANDET M, DORMONT D, CHIRAS J. (2004). Glycémie, volume de l'infarctus et pronostic de la thrombolyse. Rev Neurol (Paris), 160: 1S30-1S32.
26. SCHABITZ WR, HOFFMANN TT, HEILAND S, KOLLMAR R, BARDUTZKY J, SOMMER C, SCHWAB S. (2001). Delayed neuroprotective effect of insulin-like growth factor-i after experimental transient focal cerebral ischemia monitored with MRI. Stroke, 32: 1226-1233.
27. STOLL G. (2002). Inflammatory cytokines in the nervous system: multifunctional mediators in autoimmunity and cerebral ischemia. Rev Neurol (Paris), 158: 887-891.
28. VAUGHAN CJ, DELANTY N. (1999). Neuroprotective Properties of statins in cerebral ischemia and stroke. Stroke, 30: 1969-1973.
29. WINBECK K, POPPERT H, ETGEN T, CONRAD B, SANDER D. (2002). Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke, 33: 2459-2464.